Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06889961

Effect of Daily Mixed Spice Consumption on Memory Function

The aging process entails a multitude of structural and functional alterations within the brain, culminating in a gradual and progressive decline in cognitive function. Recent research has indicated that various spices may hold the key to enhancing brain health and combating the effects of aging on cognitive abilities. The hypothesis is that a mixture of spices, acknowledged for their reported memory protection potential, may yield a more potent beneficial effect on memory function than a single spice. The spice mixture will be used at culinary dose, and therefore side effects are anticipated. In this study, the effects of spice mixture will be evaluated, as well as their anti-oxidant, and anti-inflammatory properties. The proposed pilot study will include 50 adults (ages 50-80), exhibiting typical age-related mild cognitive decline, excluding dementia or major neurocognitive disorders. They will be randomized 1:1 assigned into a daily intake of either 4.00 g spice mixture capsules or 4.00 g maltodextrin capsules over 3 months, and explore the sustainable effect over 3 additional months. The changes in symptoms of cognition, fatigue, and mood symptoms of the spice group vs. placebo group will be compared. The outcome of the investigation of the effects of mixed spice consumption will provide important novel information on dietary recommendation of spice to preserve cognitive function in aging population.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCLA Center for Human Nutrition

Los Angeles, California, 90024, United States

Location status: Recruiting

Location contact

Hila Zelicha

CONTACT

[email protected]

+1-310-206-8292

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants are required to have clinical histories consistent with normal aging or mild cognitive impairment (MCI).
  • Age 50 to 80 years.
  • Adequate visual acuity and hearing to allow neuropsychological testing.
  • Screening laboratory tests without significant abnormalities that might interfere with the study.

-

Exclusion criteria

  • Diagnosis of probable Alzheimer's disease or any other dementia (e.g. vascular, Lewy body, frontotemporal)
  • Evidence of other neurological or physical illness that can produce cognitive deterioration. Determination of dementia will be based on the clinical evaluation including assessment of functional abilities, and cognitive screening (using the Mini Mental State Examination
  • Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale [38].
  • Uncontrolled hypertension (systolic blood pressure (BP) > 170 or diastolic BP > 100).
  • Consume spices regularly > 5g day
  • Allergy or sensitivity to spices. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of spices ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded.
  • Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria (APA, 2000).
  • Current diagnosis or alcoholism or substance addiction.
  • Eating a high fiber/polyphenol diet or taking any medication or dietary supplement which interfere with the absorption of polyphenols.
  • Frequently using prebiotics, probiotics, yogurt, and/or any fiber supplements

Treatment and study plan

Mixed spices

Dietary Supplement

Mixed spices 4.00 g capsules of spice mixture contain 1.0 g (25%) turmeric, 1.5 g (37.5%) cinnamon, 0.5 g (12.5%) oregano, 0.5 g (12.5%) black pepper, 0.3 g (7.5%) sage and 0.2 (5%) thyme

Placebo

Other

4.00 g maltodextrin capsules

Primary outcomes

  1. Memory

    Time frame: 6 month

    Verbal Episodic Memory (Rey Auditory Verbal Learning Test (RAVLT)-Revised, number of words correctly recalled after the long delay).

Secondary outcomes

  1. Executive Function

    Time frame: 6 month

    These will be measured by Trailmaking part B (time/seconds) and Wechsler Adult Intelligence Scale Version IV (WAIS-IV), DVT (Digit Span Backwards). The length of the battery is approximately 15 minutes.

  2. Language, Executive Function, Episodic Memory, Processing Speed, and Working Memory

    Time frame: 6 month

    Language, Executive Function, Episodic Memory, Processing Speed, and Working Memory will also be evaluated by The NIH Toolbox Cognition Battery (NIHTB-CB) It can be administered via computer, paper and pencil, and most recently, ipad platforms (45 mins). We will analyze, as a secondary outcome measure, the Crystallized Intelligence index.

  3. Fatigue

    Time frame: 6 month

    Fatigue (as assessed by PROMIS-Fatigue Scale, Short Form 8 items): The NIH developed Patient Reported Outcomes Measurement Information System (PROMIS®). The PROMIS Fatigue scale assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific and assess fatigue over the past seven days (5 minutes).

  4. Body weight

    Time frame: 6 month

    Body weight: Body weight will be measured at baseline, 6,12, and 24 weeks.

  5. Body composition

    Time frame: 6 month

    Body composition: Body weight and composition analysis will be performed using the Tanita-BC418 body-fat analyzer (Tanita Corp., Tokyo, Japan) based on the principles of bioelectrical impedance at baseline, 6,12, and 24 weeks.

  6. Sleep Quality

    Time frame: 6 month

    Sleep Quality, Pittsburgh Sleep Quality Index: PSQI will be employed to assess sleep quality. The PSQI is a widely recognized self-report questionnaire that evaluates sleep quality over a one-month interval. The PSQI comprises 19 self-rated items and an additional 5 items rated by bed partners or roommates. The self-rated items are used to calculate the total score, which ranges from 0 to 21. Each item on the PSQI is scored on a scale of 0 to 3, with 3 reflecting the highest level of dysfunction or disturbance. The scores of these items are then summed to compute a global PSQI score. A global PSQI score greater than 5 suggests significant sleep difficulties. A higher total score is indicative of poorer sleep quality.

  7. 24-hour Diet Recall

    Time frame: 6 month

    24-hour Diet Recall: Dietary energy and macronutrient intake will be assessed at baseline, 6,12, and 24 weeks during site visits. For the 24-hr dietary recall we will be using the Automated Self-Administered 24-hour Dietary Recall (ASA24™) tool (https://asa24.nci.nih.gov/).

  8. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Physical Functioning: Measures the ability to perform a range of physical activities without limitations, such as walking, climbing stairs, or carrying groceries.

  9. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Role-Physical: Assesses limitations in work or daily activities due to physical health problems.

  10. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Pain: Evaluates the impact of pain on daily activities and the extent of pain experienced.

  11. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    General Health: Reflects overall health perceptions, including personal health outlook and resistance to illness.

  12. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Vitality: Captures energy levels and fatigue, distinguishing between feeling energetic versus feeling tired or worn out.

  13. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Social Functioning: Measures the impact of physical or emotional health on social activities and interactions with others.

  14. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Role-Emotional: Assesses the extent to which emotional problems interfere with work or other daily activities.

  15. Quality of life, SF-36

    Time frame: 6 month

    The SF-36 domain:

    Mental Health: Evaluates psychological well-being, including feelings of depression, anxiety, and overall emotional stability.

Other outcomes

  1. Blood anti-oxidation capacity

    Time frame: 6 month

    Blood anti-oxidation capacity will be measured using Oxygen radical antioxidant capacity (ORAC) and trolox equivalent antioxidant capacity (TEAC) assays.

  2. Plasma inflammatory panel

    Time frame: 6 month

    Plasma inflammatory panel will be measured using the Luminex MagPix® analyzer (Luminex, Austin TX)

  3. Fecal microbiome

    Time frame: 6 month

    Fecal microbiome will be analyzed at UCLA microbiome core

  4. Mitochondrial function

    Time frame: 6 month

    Mitochondrial function as well as aging markers will be evaluated using blood samples at the UCLA Mitochondrial Metabolism core and Center for Human Nutrition Analytical Laboratory.

Study contacts

Contact information is provided by the study sponsor or research team.

Hila Zelicha, RD PHD

CONTACT

[email protected]

+1-310-206-8292

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Official study title

Effect of Daily Mixed Spice Consumption on Memory in Middle-Aged and Older Adults With Age-related Cognitive Decline: A Pilot Study

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 21, 2025
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.